Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.
This study has been completed.
Sponsor:
Eli Lilly and Company
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00105092
First received: March 4, 2005
Last updated: April 27, 2007
Last verified: April 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | February 2007 |
| Estimated Primary Completion Date: | No date given |